Propofol injection pain. Other and unspecified general anaesthetics
Conditions
Interventions
Intervention 1: patients in ondansetron group: received four milligrams ondansetron. Intervention 2: Patients in magnesium sulfate group: received 150 mg magnesium sulfate. Intervention 3: patients in
Prevention
Treatment - Drugs
Placebo
patients in ondansetron group: received four milligrams ondansetron
Patients in magnesium sulfate group: received 150 mg magnesium sulfate
patients in placebo group: 3 milliliter normal saline 0.9%
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion:patients undergoing vitrectomy operation using general anesthesia with American Society of Anesthesiologists physical status I and II. Exclusion: known sensitivity to propofol or ondansetron; receiving analgesic or sedative medication in the last 24 hours; presence of infection on the dorsum of the left hand; indications for rapid sequence intubation; presence of cardiac conduction defects; epilepsy; and use of antiarrhythmic medications, thin dorsal veins, renal and liver diseases, neuro-muscular diseases, pregnant women, and uncooperative patients were excluded
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Propofol injection pain. Timepoint: 5, 10, 20 and 25 seconds after trial intervention. Method of measurement: with 4 points scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Amir Bahrami-Ahmadi
Iran University of Medical Sciences
Outcome results
None listed